BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

06 3 2023 15:05:38 提供 Nasdaq GlobeNewswire

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events

06 3 2023 06:00:00 提供 Nasdaq GlobeNewswire

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

03 3 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

23 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

17 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

13 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in February and March Investor Events

08 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

04 1 2023 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

22 12 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in November Investor Events

09 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

03 11 2022 06:30:01 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

17 10 2022 11:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

14 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

13 10 2022 15:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)

11 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

07 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

20 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in September Investor Events

06 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

18 8 2022 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

10 8 2022 06:30:00 提供 Nasdaq GlobeNewswire